Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
High Grade Glioma
Interventions
DRUG

O-(2-[18F]Fluoroethyl)-L-tyrosine, [18F]-FET with PET/MRI

High grade glioma patients that are planning to undergo radiation therapy (RT) and consent to this study will have up to 3 in-person study visits. The first visit will take up to 2 hours, the second visit will take up to 3 hours, and the third visit will take up to 6 hours. After both imaging visits, there will be a phone call at 24-48 hours after imaging.After confirmation of patient eligibility and consent, the administration of FET and FMISO and related procedures will be performed in the UAB Advanced Imaging Facility (AIF) at the time of first standard of care (SOC) MRI after completion of RT (typically a 4-week interval). Patients enrolled in the study will be followed clinically and with standard of care brain MRI. PFS and OS will be monitored for up to 24 months after completion of FET and FMISO PET/MRI studies. Study participants will not undergo additional study related procedures after completion of the FET-PET/MRI and FMISO-PET/MRI studies.

Trial Locations (2)

35249

NOT_YET_RECRUITING

UAB, Birmingham

RECRUITING

UAB, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER